In vitro and in vivo genetic stability studies of a human adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB)

Knowles, M. Kimberly; Roberts, Danielle Renee; Craig, Sheona; Sheen, Mary; Nadin-Davis, Susan A.; Wandeler, Alexander I.

doi:10.1016/j.vaccine.2009.02.074

Cited by 28 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), one of the few species susceptible to human adenovirus infection (Knowles et al 2009a). Knowles et al (2009b) reported no adverse histologic effects for AdRG1.3 PCR-Southern Blot positives (18/1,280; 1.4%) and negative tissue samples obtained from experimental vaccinates or contact animals. Likewise, no histopathologic lesions were observed in a companion captive study for this field trial in the Virginia opossum, eastern cottontail rabbit (Sylvilagus floridanus), turkey (Meleagris gallopavo), eastern fox squirrel (Sciurus niger), and wood rat (Neotoma sp.)…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

SAFETY AND IMMUNOGENICITY OF ONTARIO RABIES VACCINE BAIT (ONRAB) IN THE FIRST US FIELD TRIAL IN RACCOONS (PROCYON LOTOR)

Slate

Chipman

Algeo

et al. 2014

Journal of Wildlife Diseases

View full text Add to dashboard Cite

ABSTRACT:In 2011, we conducted a field trial in rural West Virginia, USA to evaluate the safety and immunogenicity of a live, recombinant human adenovirus (AdRG1.3) rabies virus glycoprotein vaccine (Ontario Rabies Vaccine Bait; ONRAB) in wild raccoons (Procyon lotor) and striped skunks (Mephitis mephitis). We selected ONRAB for evaluation because of its effectiveness in raccoon rabies management in Ontario and Quebec, Canada, and significantly higher antibody prevalence rates in raccoons compared with a recombinant vaccinia-rabies glycoprotein (V-RG) vaccine, Raboral V-RGH, in US-Canada border studies. Raccoon rabies was enzootic and oral rabies vaccination (ORV) had never been used in the study area. We distributed 79,027 ONRAB baits at 75 baits/km 2 mostly by fixed-wing aircraft along parallel flight lines at 750-m intervals. Antibody prevalence was significantly higher at 49.2% (n5262) in raccoons after ONRAB was distributed than the 9.6% (n5395) before ORV. This was the highest antibody prevalence observed in raccoons by US Department of Agriculture Wildlife Services for areas with similar management histories evaluated before and after an initial ORV campaign at 75 baits/km 2 with Raboral V-RG. Tetracycline biomarker (TTCC) was significantly higher among antibodypositive raccoons after ONRAB baiting and was similar among raccoons before ORV had been conducted, an indication of vaccine-induced rabies virus-neutralizing antibody production following consumption of bait containing TTCC. Skunk sample size was inadequate to assess ONRAB effects. Safety and immunogenicity results supported replication of this field trial and led to a recommendation for expanded field trials in 2012 to evaluate safety and immunogenicity of ground-distributed ONRAB at 150 baits/km 2 in residential and commercial habitats in Ohio, USA and aerially distributed ONRAB at 75 baits/km 2 in rural habitats along US-Quebec border.

show abstract

Section: Discussionmentioning

confidence: 93%

“…No AdRG1.3 was detected in wild-captured animals within the ONRAB field trial zone on days 5 or 6. Knowles et al (2009b) reported excretion of the vaccine in the oral cavity at 0.8% of oral swabs and 6.8% of fecal specimens from experimental animals subjected to oral instillation. One skunk shed a small amount of virus in feces on day 14.…”

Section: Discussionmentioning

confidence: 99%

SAFETY AND IMMUNOGENICITY OF ONTARIO RABIES VACCINE BAIT (ONRAB) IN THE FIRST US FIELD TRIAL IN RACCOONS (PROCYON LOTOR)

Slate

Chipman

Algeo

et al. 2014

Journal of Wildlife Diseases

View full text Add to dashboard Cite

show abstract

“…The ONRAB ® vaccine employs a replication-competent HAdV-5 vector into which a DNA copy of the ERA virus glycoprotein gene has been inserted [ 128 , 129 ] and, similarly to V-RG, is packaged into sachets for oral administration to wildlife. Results from fi eld trials in Canada have indicated that ONRAB is stable both in vitro and in vivo, with a limited ability to replicate in an established model for human adenovirus infection and is suitable for environmental use as an oral rabies vaccine for wildlife [ 130 ].…”

Section: Basic Epidemiologic Methodsmentioning

confidence: 99%

Rhabdovirus: Rabies

Christian

Rupprecht

2014

Viral Infections of Humans

View full text Add to dashboard Cite

show abstract

“…The V-RG vaccine has been used as an oral vaccine in red foxes in several western European countries, raccoons, gray foxes, and coyotes in North America, raccoons in Canada, and raccoon dogs in Korea [11, 12, 15, 16]. Several studies have described human adenovirus recombinants expressing the rabies G protein [17–19]. The first construct, AdRG1, was developed by inserting the rabies G gene from the ERA strain into the E3 region [17, 19].…”

Section: Introductionmentioning

confidence: 99%

Comparison of the protective efficacy between single and combination of recombinant adenoviruses expressing complete and truncated glycoprotein, and nucleoprotein of the pathogenic street rabies virus in mice

Kim

Yang

Nah

et al. 2017

Virol J

View full text Add to dashboard Cite

BackgroundRabies is an important viral zoonosis that causes acute encephalitis and death in mammals. To date, several recombinant vaccines have been developed based on G protein, which is considered to be the main antigen, and these vaccines are used for rabies control in many countries. Most recombinant viruses expressing RABV G protein retain the G gene from attenuated RABV. Not enough is currently known about the protective effect against RABV of a combination of recombinant adenoviruses expressing the G and N proteins of pathogenic street RABV.MethodsWe constructed a recombinant adenovirus (Ad-0910Gsped) expressing the signal peptide and ectodomain (sped) of G protein of the Korean street strain, and evaluated the immunological protection conferred by a single and combination of three kinds of recombinant adenoviruses (Ad-0910Gsped and Ad-0910G with or without Ad-0910 N) in mice.ResultsA combination of Ad-0910G and Ad-0910 N conferred improved immunity against intracranial challenge compared to single administration of Ad-0910G. The Ad-0910G virus, expressing the complete G protein, was more immunogenic than Ad-0910Gsped, which expressed a truncated G protein with the transmembrane and cytoplasmic domains removed. Additionally, oral vaccination using a combination of viruses led to complete protection.ConclusionsOur results suggest that this combination of viruses is a viable new intramuscular and oral vaccine candidate.

show abstract

In vitro and in vivo genetic stability studies of a human adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB)

Cited by 28 publications

References 27 publications

SAFETY AND IMMUNOGENICITY OF ONTARIO RABIES VACCINE BAIT (ONRAB) IN THE FIRST US FIELD TRIAL IN RACCOONS (PROCYON LOTOR)

SAFETY AND IMMUNOGENICITY OF ONTARIO RABIES VACCINE BAIT (ONRAB) IN THE FIRST US FIELD TRIAL IN RACCOONS (PROCYON LOTOR)

Rhabdovirus: Rabies

Comparison of the protective efficacy between single and combination of recombinant adenoviruses expressing complete and truncated glycoprotein, and nucleoprotein of the pathogenic street rabies virus in mice

Contact Info

Product

Resources

About